The strong preclinical data de-risks KRRO-111's mechanism and supports its dual lung/liver potential, but human translation remains unproven. Watch for the regulatory submission in H1 2027 and any early clinical data readouts.
Price Chart
Executive Summary
Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), showing >95% SERPINA1 mRNA editing, ~6-fold increase in total AAT, and 95% reduction of pathogenic Z-AAT in mouse models. The company plans a regulatory submission in the first half of 2027. This is a non-financial, pipeline-stage catalyst for a clinical-stage biotech with no revenue.
Key Facts
- KRRO-111 achieved >95% SERPINA1 mRNA editing in repeat-dose mouse studies.
- Total AAT concentrations reached 172 µM (~6-fold vs. vehicle) at Day 57.
- KRRO-111 reduced whole liver Z-AAT levels by 95% relative to vehicle control.
- Regulatory submission for KRRO-111 expected in first half of 2027.
- KRRO-111 is a GalNAc-conjugated RNA-editing oligonucleotide administered subcutaneously.
Financial Impact
No financial figures reported; pre-revenue clinical-stage biotech. The data supports pipeline value and potential regulatory milestone.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- Regulatory submission timeline could slip beyond H1 2027.
- Competition from other AATD therapies (e.g., augmentation therapy, gene-editing approaches).
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-428306 |
| Document: krro-ex99_1.htm | 0001193125-26-428306 |
| Document: 0001193125-26-428306-index-headers.html | 0001193125-26-428306 |
| Document: 0001193125-26-428306-index.html | 0001193125-26-428306 |
| Document: 0001193125-26-428306.txt | 0001193125-26-428306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Insider Buy | $12.46 | awaiting T+1 | — | $12.02 (−3.53%) |
Oct 22, 2026 4d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $12.02 (−0.25%) |
Oct 16, 2026 10d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $12.02 (+34.90%) |
Oct 5, 2026 21d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Oct 5, 2026 21d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $12.02 (−13.09%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $12.02 (−9.56%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $12.02 (−0.83%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $12.02 (−15.94%) |
Jun 24, 2026 17w ago | Insider Cluster | $12.17 $12.70 | ▼ −4.36% | ▼ −5.08% | $12.02 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers